Although most of the patients had metabolic syndrome, more studies will be required to confirm and extend these observations; nevertheless, alteration in PKCβ expression implies that pharmacologic intervention of PKCβ may have broad therapeutic utility. This evidence concerns the gene PRKCB and metabolic syndrome.